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Abstract
Aims: The TWENTE trial recently enrolled more than 80% of all eligible patients, who were randomised to 
zotarolimus-eluting Resolute or everolimus-eluting XIENCE V stents. In the present study, we investigated 
whether eligible, non-enrolled patients differed from the randomised TWENTE trial population in baseline 
characteristics and one-year outcome.
Methods and results: Characteristics of 1,709 eligible patients were analysed. Independent external adju-
dication of clinical events was likewise performed for non-enrolled (n=318) and randomised patients 
(n=1,391). Non-enrolled and randomised patients did not differ in gender distribution, diabetes mellitus, and 
clinical presentation, but differed significantly in age and cardiovascular history. Nevertheless, clinical out-
come after one year did not differ in the primary composite endpoint target-vessel failure (TVF; 9.8% vs. 
8.1%; p=0.34), and its components cardiac death (1.6% vs. 1.2%; p=0.61), target vessel-related myocardial 
infarction (4.7% vs. 4.6%; p=0.92), and target-vessel revascularisation (3.8% vs. 3.0%; p=0.48). Previous 
bypass surgery predicted TVF in non-enrolled patients (p=0.001); removal of these patients resulted in identi-
cal TVF rates for non-enrolled and randomised patients (7.3% vs.  7.3%; p=0.99).
Conclusions: Despite some differences in baseline characteristics, non-enrolled and randomised patients 
did not differ in one-year outcome, which was favourable for both populations and may be related to the drug-
eluting stents used.
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Abbreviations
CABG coronary artery bypass grafting
DES drug-eluting stent
PCI percutaneous coronary intervention
STEMI ST-elevation myocardial infarction
TVF target-vessel failure
TVR target-vessel revascularisation
Non-STE-ACS non-ST-elevation acute coronary syndromes 
Introduction
Drug-eluting stents (DES) have been rapidly adapted for routine per-
cutaneous coronary interventions (PCI), as they reduced the need for 
reinterventions.1,2 As first-generation DES did not improve mortal-
ity,3-6 novel stents with different coatings were developed, aimed at 
improved clinical outcome.7,8 Two of these so-called second-genera-
tion DES are the zotarolimus-eluting Resolute stent (Medtronic, 
Minneapolis, MN, USA) and the everolimus-eluting XIENCE V 
stent (Abbott Vascular, Santa Clara, CA, USA). Both DES have thin-
strut, open-cell, cobalt-chromium-based stent platforms and thin, 
durable polymer-based coatings,9,10 and they have shown favourable 
clinical results that have led to widespread use in clinical practice.11-16 
For these stents, non-inferiority with regard to safety and efficacy 
was recently demonstrated by TWENTE, a randomised, controlled 
study in a patient population with advanced coronary disease and 
complex lesions,17 which confirmed with relatively low event rates 
the results of the RESOLUTE All-Comers trial.18 In addition, 
TWENTE is one of the relatively few randomised comparative DES 
trials that have been performed in a study population with very lim-
ited exclusion criteria to reflect routine clinical practice.18-21
The enrolment in the randomised TWENTE trial was high, com-
prising more than 80% of all eligible patients.17 However, it is 
unknown whether the non-enrolled patients, who were all likewise 
treated with Resolute and XIENCE V stents, differ from the ran-
domised TWENTE trial population in terms of baseline characteris-
tics or –perhaps even more relevant– in clinical outcome. To answer 
this question, we prospectively recorded comprehensive data sets on 
clinical, procedural, and angiographic characteristics of all eligible 
but non-enrolled patients in the Non-Enrolled TWENTE study. To 
assure high-quality clinical outcome data and to facilitate meaningful 
comparisons with the findings of the randomised TWENTE trial, an 
external clinical research organisation performed the independent 
adjudication of all clinical events together in both the Non-Enrolled 
TWENTE study and randomised TWENTE trial.
Methods
STUDY DESIGN AND PATIENT POPULATIONS
Details of the randomised TWENTE trial, which was performed 
from June 18, 2008 to August 26, 2010 at Thoraxcentrum Twente in 
Enschede, The Netherlands, have previously been reported.17 
TWENTE is a randomised, controlled, patient-blinded DES trial, 
comparing Resolute and XIENCE V stents after 1:1 randomisation 
(ClinicalTrials.gov NCT01066650). Patients were eligible for 
enrolment and randomisation if they were aged 18 years or older, 
were capable of providing informed consent, and underwent a PCI 
with DES implantation for the treatment of chronic stable coronary 
artery disease or non-ST-elevation acute coronary syndromes (non-
STE-ACS). To include a broad study population, the study protocol 
defined no limit for lesion length, reference vessel size, and number 
of target lesions or vessels. The only exclusion criteria were: ST-
elevation myocardial infarction (STEMI) or STEMI-equivalent 
requiring primary or rescue PCI during the past 48 hours; planned 
staged revascularisation; renal failure requiring haemodialysis; 
serious conditions that could limit the patient’s ability to participate 
in study procedures, in particular life expectancy <1 year; participa-
tion in investigational drug or device study; if the choice of stent 
type was dictated by logistic reasons (e.g., a stent with required 
dimensions only available as one type).17
During the course of the randomised TWENTE trial, patients who 
were not enrolled were also treated with one of both, Resolute or 
XIENCE V stents, and their clinical course was prospectively registered 
as part of the Non-Enrolled TWENTE study. Operators were asked to 
report reasons for non-enrolment in PCI reports but incomplete docu-
mentation of this detail was not infrequent. We therefore used PCI 
reports, all clinical records, and interviews with the operators and other 
medical staff involved to obtain the most reliable estimate of the reasons 
for non-enrolment. The Non-Enrolled TWENTE study and the previ-
ously reported randomised TWENTE trial complied with the Declaration 
of Helsinki for investigation in human beings, and were performed after 
approval and supervision of our institutional ethics committee.
INTERVENTION, MEDICATION, ELECTROCARDIOGRAPHY, 
AND LABORATORY TESTING
PCI procedures were performed according to standard techniques 
as previously described.17 In brief, lesion predilatation, direct stent-
ing, and/or stent postdilatation were permitted at the operators’ dis-
cretion; liberal use of stent postdilatation was encouraged. 
Pharmacological therapy before, during, and after PCI as well as 
systematic laboratory and electrocardiographic testing were per-
formed as previously described.17
DEFINITIONS OF CLINICAL ENDPOINTS
Definitions of clinical endpoints have been fully described in the 
main report on the randomised TWENTE trial.17 The same endpoint 
definitions were used in the present study. In general, the definitions 
of the Academic Research Consortium (ARC) were applied.22,23 In 
brief, the primary endpoint target-vessel failure (TVF) was defined as 
(in hierarchical order) cardiac death, target-vessel-related myocardial 
infarction, or clinically driven target-vessel revascularisation (TVR) 
by re-PCI or surgery. Cardiac death was defined as any death due to 
proximate cardiac cause, un-witnessed death and death of unknown 
cause, and all procedure-related deaths, including those related to 
concomitant treatment. Classification and location of myocardial 
infarction was performed based on laboratory testing, electrocardio-
graphic parameters, angiographic information, and clinical data.17 
Laboratory parameters for definition of myocardial infarction was 
any creatine kinase concentration of more than double the upper limit 
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of normal with elevated values of a confirmatory cardiac biomarker.23 
TVR was defined as any repeat coronary revascularisation of the tar-
get vessel. Target-vessel (or target-lesion) revascularisation was con-
sidered clinically indicated if the angiographic percent diameter 
stenosis of the then treated lesion was ≥50% in the presence of 
ischaemic signs or symptoms, or if the diameter stenosis was ≥70% 
irrespective of ischaemic signs or symptoms.22
Secondary clinical endpoints are: death from any cause; Q-wave 
and non-Q-wave myocardial infarction; any myocardial infarction; 
TVR by PCI, surgery, or either or both; clinically-indicated target-
lesion revascularisation; any target-lesion revascularisation (stented 
segment including 5 mm proximal and distal border-zones); stent 
thrombosis, defined according to ARC.22 Composite parameters are 
(where applicable in a hierarchical order): Target-lesion failure, 
defined as a composite of cardiac death, target-vessel-related myo-
cardial infarction, and clinically-indicated target-lesion revasculari-
sation; and major adverse cardiac events, a composite of all-cause 
death, any myocardial infarction, emergent coronary artery bypass 
surgery or clinically indicated target lesion revascularisation.
DATA ACQUISITION AND FOLLOW-UP
In-hospital adverse events were recorded prior to discharge. As part 
of our centre’s standard follow-up procedure, 12-month follow-up 
data of all patients were obtained at visits to outpatient clinics or, if 
not feasible, by telephone follow-up and/or a medical question-
naire. For any event trigger, members of the study team gathered all 
clinical information available from referring cardiologist, general 
practitioner, and/or hospital involved.
INDEPENDENT CLINICAL EVENT ADJUDICATION
Processing of clinical data and adjudication of adverse clinical 
events of the Non-Enrolled TWENTE population were performed 
independently in the same way as for the randomised TWENTE 
trial (use of anonymous patient data and blinding for stent type) by 
Cardialysis in Rotterdam, The Netherlands. In brief, the clinical 
event committee adjudicated any death, potential myocardial 
infarction, stent thrombosis, and revascularisation.
STATISTICAL ANALYSIS
Data analysis was performed with the Statistical Package for Social 
Sciences (SPSS, version 17; SPSS Inc., Chicago, IL, USA). Data were 
reported as frequencies and percentages for dichotomous and categori-
cal variables and as mean ± standard deviation for continue variables. 
The chi-square test and the Fisher’s exact test were used as appropriate. 
The student’s t-test was used to test normally distributed parameters. 
The Kaplan–Meier method was used to calculate the time to clinical 
endpoints and the Log-rank test was used to compare between-group 
differences. As non-enrolled patient populations are likely to contain 
more high-risk patients with a higher event rate,24 multiple logistic 
regression analysis was applied to the data of the non-enrolled patient 
population in order to identify predictors of TVF. In a subsequent anal-
ysis, we excluded patients with these variables to correct for potential 
confounders. Unless otherwise specified, a two-sided p value <0.05 
was considered to indicate statistical significance.
Results
During the inclusion period of the randomised TWENTE trial, 
2,239 patients were treated with DES at Thoraxcentrum Twente, 
The Netherlands. A total of 1,709 of these patients were eligible for 
study enrolment and randomisation. Finally, 1,391 of these 1,709 
patients (81.4%) with 2,116 lesions were enrolled in the randomised 
TWENTE trial. In other words, only 318 eligible patients (18.6%, 
with 466 lesions) were not enrolled in the randomised trial but were 
assessed in the Non-Enrolled TWENTE study (Figure 1).
2,239 patients treated with DES during the study period
530 patients not meeting TWENTE trial inclusion criteria
(including 348 patients with primary PCI)
1,709 patients eligible for enrolment in the TWENTE trial
318 (18.6%) eligible patients not enrolled in the randomised
trial but registered in the Non-Enrolled TWENTE study
1,391 (81.4%) eligible patients enrolled in the randomised
controlled TWENTE trial
Figure 1. Flow chart of patients treated with DES during the course of the randomised TWENTE trial. Patients of the Non-Enrolled TWENTE 
study and the randomised TWENTE trial were compared. *Data of the randomised TWENTE trial have previously been reported.17
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REASONS FOR NON-ENROLMENT
Reasons for non-enrolment and estimates of their incidence within 
the non-enrolled population were: (1) refusal of the patient to partici-
pate in the randomised trial (~10%); (2) uncertainty of the operator 
whether the information transfer was successful (e.g., because of lan-
guage barrier, deafness, or the entire clinical condition) (~25%); (3) 
logistic reasons (e.g., an ACS patient is not informed prior to the 
catheterisation, while another patient is announced for primary PCI) 
(~15%); and (4) omission of informing the patient about the trial 
prior to an elective procedure (~30%). This means that a substantial 
proportion of the eligible patients (~20%; i.e., ~3.7% of all eligible 
patients) were not enrolled without evident reason.
PATIENTS, TARGET LESIONS, AND PCI PROCEDURES
Table 1 compares demographics and the procedural characteristics 
of both the Non-Enrolled TWENTE study population versus the 
Table 1. Characteristics of patients and procedures.
Non-enrolled 
patients 
(N=318)
Randomised 
patients 
(N=1,391)
p-value
Age (yrs ) 66.0 (10.9) 64.2 (10.8) 0.01
Men 224 (70.4) 1009 (72.5) 0.45
Diabetes mellitus (any) 72 (22.6) 301 (21.6) 0.66
Chronic renal failure* 21 (6.6) 38 (2.7) 0.001
Arterial hypertension 185 (58.2) 773 (55.6) 0.40
Hypercholesterolaemia 193 (60.7) 803/1357 (59.2) 0.06
Current smoker 70 (22.0) 340 (24.4) 0.36
Family history of CAD 102/193 (52.8) 740 (53.2) 0.93
Myocardinfarction (any) 137 (43.1) 450 (32.4) <0.001
Previous PCI 92 (28.9) 288 (20.7) 0.001
Previous CABG 54 (17.0) 148 (10.6) 0.002
Clinical characteristic 0.48
Stable angina pectoris 151 (47.5) 674 (48.5)
Acute coronary syndrome 167 (52.5) 717 (51.5)
Unstable angina 84 (26.4) 325 (23.4)
Non-ST-elevation MI 83 (26.1) 392 (28.2)
Left ventricular ejection fraction <30%¶ 13/199 (6.5) 32/1051 (3.0) 0.015
Multivessel treatment 61 (19.2) 336 (24.2) 0.06
Total no lesions treated per patient 0.28
One lesion treated 203 (63.8) 857 (61.6)
Two lesions treated 92 (28.9) 393 (28.3)
Three of more lesions treated 23 (7.2) 141 (10.1)
At least one CTO 28 (8.8) 95 (6.8) 0.22
At least one bifurcation 83 (26.1) 362 (26.0) 0.98
At least one in-stent restenosis 43 (13.5) 69 (5.0) <0.001
Postdilatation 278 (87.4) 1222 (87.9) 0.83
Data are number (%) or mean (SD); CAD: coronary artery disease; PCI: percutaneous coronary 
intervention; CABG: coronary artery bypass grafting; MI: myocardial infarction; CTO: chronic 
total occlusion; * Chronic renal failure was defined by serum creatinine level ≥130 µmol/L; 
¶Left ventricular ejection fraction was assessed with ultrasound, MRI or LV angiography
Table 2. Lesion characteristics.
Non-enrolled 
(N=466 
lesions)
Randomised 
(N=2,116 
lesions)
p-value
Target lesion coronary artery
Left main 17 (3.6) 54 (2.6) 0.19
Left anterior descendens 179 (38.4) 878 (41.5) 0.22
Left circumflex 107 (23.0) 483 (22.8) 0.95
Right coronary artery 135 (29.0) 653 (30.9) 0.42
Bypass graft 28 (6.0) 48 (2.3) <0.001
ACC-AHA lesion class 0.047
A 24 (5.2) 154 (7.3)
B1 87 (18.7) 478 (22.6)
B2 153 (32.8) 678 (32.0)
C 202 (43.3) 806 (38.1)
De novo lesions 409 (87.8) 1999 (94.5) <0.001
Chronic total occlusion 30 (6.4) 100 (4.7) 0.13
In stent restenosis 37 (7.9) 75 (3.5) <0.001
Bifurcated lesion 101 (21.7) 518 (24.5) 0.20
Data are number (%); ACC: American College of Cardiology; AHA: American Heart Association; 
De novo lesions include chronic total occlusion, but not grafts and in-stent restenosis
randomised TWENTE trial population. Both study populations did 
not differ in the proportion of genders, diabetes mellitus, and clini-
cal presentation (acute coronary syndromes in 52.5% vs. 51.5%, 
respectively; p=0.48). Non-enrolled patients were somewhat older 
(66.0±10.9 vs. 64.2±10.8 years; p=0.01). There was a trend towards 
less multivessel treatment in the non-enrolled patients (19.2% vs. 
24.2%; p=0.06), matching with a more severely impaired left ven-
tricular (6.5% vs. 3.0%; p=0.015) and renal function (6.6% vs. 
2.7%; p=0.001) in this group. In addition, non-enrolled patients 
more often had a history of previous MI (43.1% vs. 32.4%; 
p<0.001), previous PCI (28.9% vs. 20.7%; p=0.001), and previous 
coronary artery bypass grafting (CABG) (17.0% vs. 10.6%; p=0.002; 
Table 1). A total of 466 and 2,116 lesions were treated in the Non-
Enrolled TWENTE study and the randomised TWENTE trial, 
respectively (Table 2). Target lesions of non-enrolled patients more 
often showed complex B2 or C lesion types (76.1% vs. 70.1%; 
p=0.047). In parallel with the higher incidence of a history of PCI 
and/or CABG in the Non-Enrolled TWENTE population, more target 
lesions were restenoses and bypass graft lesions (p<0.001 for both; 
Table 2).
CLINICAL OUTCOME
Clinical follow-up data were available for 316 patients of the Non-
Enrolled TWENTE study (99.4% follow-up data) and 1,387 ran-
domised TWENTE patients (100% follow-up data available; four 
patients withdrew consent). Table 3 and Figure 2 show various clini-
cal outcome parameters at one-year follow-up. Between both popu-
lations, there was no significant difference in the primary outcome 
parameter TVF (9.8% vs. 8.1%; p=0.34, OR 1.23 [95% CI 0.81 to 1.8]). 
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There was also no significant difference in the components of the 
primary endpoint (cardiac death [1.6% vs. 1.2%; p=0.61]; target 
vessel-related MI [4.7% vs. 4.6%; p=0.92]; and clinically driven 
TVR [3.8% vs. 3.0%; p=0.48]), and any other clinical endpoint, 
such as death from any cause (2.2% vs. 2.1%; p=0.89) and major 
adverse cardiac events (9.5% vs. 9.5%; p=0.99; Table 3).
STENT THROMBOSIS
Within the non-enrolled patient population, there was no definite 
stent thrombosis (Table 3). Definite or probable stent thrombosis 
occurred in one patient of the Non-Enrolled TWENTE population 
(one probable stent thrombosis) and in 14 patients of the ran-
domised TWENTE trial population (0.3% vs. 1.0%; p=0.23).
Table 3. Clinical outcome after one year.
Non-enrolled 
patients 
(N=316)
Randomised 
patients 
(N=1,387)
p-value
Target vessel failure 31 (9.8) 113 (8.1) 0.34
Death
Any cause 7 (2.2) 29 (2.1) 0.89
Cardiac cause 5 (1.6) 17 (1.2) 0.61
Target vessel related MI
Any 15 (4.7) 64 (4.6) 0.92
Q-wave 0 11 (0.8) 0.11
Non-Q-wave 15 (4.7) 53 (3.8) 0.45
Periprocedural MI 13 (4.1) 57 (4.1) 0.99
Clinically indicated TVR
Any 12 (3.8) 42 (3.0) 0.48
Percutaneous 12 (3.8) 33 (2.4) 0.16
Surgical 0 9 (0.6) 0.15
Target lesion failure 28 (8.9) 102 (7.4) 0.36
Clinically indicated TLR
Any 9 (2.8) 29 (2.1) 0.41
Percutaneous 9 (2.8) 22 (1.6) 0.13
Surgical 0 7 (0.5) 0.21
Death from cardiac causes or 
target-vessel MI
20 (6.3) 67 (4.8) 0.28
Major adverse cardiac events 30 (9.5) 132 (9.5) 0.99
Definite ST (0-360 days)
all patients 0 4 (0.6) 0.34
Probable ST (0-360 days)
all patients 1 (0.3) 10 (0.7) 0.42
ST (0-360 days)
Possible 3 (0.9) 6 (0.4) 0.25
Definite or probable 1 (0.3) 14 (1.0) 0.23
Definite, probable or possible 4 (1.3) 20 (1.4) 0.81
Data are number of patients (%); MI: myocardial infarction; TVR: target vessel 
revascularisation; TLR: target lesion revascularisation; ST: stent thrombosis; Major adverse 
cardiac events is a composite of all cause death, any myocardial infarction, emergent 
coronary-artery bypass surgery or clinically indicated target lesion revascularisation
PREDICTORS OF TARGET VESSEL FAILURE
The only parameter that significantly predicted TVF in the Non-
Enrolled TWENTE population was a history of CABG (OR 3.7, 95% 
CI 1.67–8.15; p=0.001). After removal of patients with a history of 
CABG from the analyses (54/316 non-enrolled [17%] and 148/1,386 
randomised patients [10.6%]), differences in baseline characteristics 
were virtually unchanged: the Non-Enrolled TWENTE population 
still comprised older patients (65.3±11.1 vs. 63.7±10.9 years; p=0.03) 
and more patients with severely impaired left ventricular function 
(6.2% vs. 2.6%; p=0.02), impaired renal function (5.3% vs. 2.6%; 
p=0.02), history of previous MI (42.8% vs. 31.5%; p<0.001), and 
history of previous PCI (24.6% vs. 18.8%; p=0.03). However, 
removal of patients with a history of CABG resulted in identical TVF 
rates for Non-Enrolled TWENTE patients and the randomised 
TWENTE population (7.3% [19/262] vs. 7.3% [90/1,239]; p=0.99). 
Moreover, the slight numerical differences in other clinical endpoints 
continued to be statistically non-significant (major adverse cardiac 
events 8.0% [21/262] vs. 8.6% [106/1,239]; p=0.78).
Discussion
In the present study, we addressed the question of whether patients, 
who were not enrolled in the randomised TWENTE trial17 but were 
all likewise treated with Resolute or XIENCE V stents, differed 
from the enrolled and randomised patients in baseline characteris-
tics, procedural details, or clinical outcome. During the course of the 
randomised TWENTE trial, only 19 percent of the eligible patients 
were not enrolled in the randomised trial.17 To assure high-quality 
clinical outcome data and to facilitate meaningful comparisons, an 
independent external clinical research organisation performed the 
clinical event adjudication for both the Non-Enrolled TWENTE 
population and the randomised TWENTE population (together in 
the same adjudication session). The randomised TWENTE popula-
tion comprised many complex patients and advanced coronary 
lesions,17 and in the Non-Enrolled TWENTE population many 
patients showed similar baseline characteristics and cardiovascular 
risk factors. Nevertheless, Non-Enrolled TWENTE patients were on 
average slightly older and more frequently showed a history of pre-
vious myocardial infarction and/or coronary revascularisations. As a 
consequence, we also identified mild but statistically significant dif-
ferences in the rates of heart failure, renal failure, and lesion com-
plexity in favour of the randomised TWENTE trial population, 
which comprised less bypass graft lesions and restenoses.
Despite the slight aforementioned baseline differences, the Non-
Enrolled TWENTE population and the randomised TWENTE trial 
patients showed no significant difference in clinical outcome 
parameters such as TVF (9.8% vs. 8.1%; p=0.34), all-cause mortal-
ity (2.2% vs. 2.1%; p=0.89), or major adverse cardiac events (9.5% 
vs. 9.5%; p=0.99). Our data suggest that if all 1,709 consecutive 
eligible patients had entered the randomised trial, the overall TVF 
rate could have been as low as 8.5%. In fact, this study underlines 
the high clinical performance of the second-generation DES that 
were used. This performance appears to be greatly independent of 
the clinical profile of the patients.
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COMPARISON WITH PREVIOUS STUDIES
Compared to RESOLUTE All-Comers trial18 and COMPARE 
trial,20 two randomised studies with second-generation DES in 
“real-world” patient populations, the randomised TWENTE 
patients showed similar or slightly higher rates of previous MI 
(32.4% vs. 16.5-29.7%), previous PCI (20.7% vs. 13.5-32%), pre-
vious CABG (10.6% vs. 6.5-9.8%), heart failure (3.0% vs. 2.5%), 
in-stent restenosis lesions (5.0% vs. 2.5-8.1%), bypass graft lesions 
(2.3% vs. 2.0-2.5%), and their age was similar (mean age 64.2 vs. 
63.3-64.3 years). Accordingly, it is fair to state that the randomised 
TWENTE trial17 is a study in a “real-world” patient population 
(with the exception of acute STEMI), providing data that is highly 
relevant for routine clinical practice.
Analyses of randomised intervention studies that compared PCI 
and CABG have demonstrated that patient characteristics and the 
clinical outcome of these studies differed significantly from routine 
clinical practice.24 Selection bias is more likely to be undetectable 
in studies with low enrolment rates, but in the randomised TWENTE 
trial the enrolment rate was particularly high. In many Non-Enrolled 
TWENTE patients there was at least one reason for non-enrolment. 
Nevertheless, in approximately 3.7% of all eligible patients the 
main reason for non-enrolment could not be identified. This leaves 
room for potential selection bias, and in fact, the differences in 
baseline characteristics between the Non-Enrolled TWENTE study 
population and the randomised TWENTE trial patients suggest that 
there could have been some selection bias. Examples of patients 
whom operators may deliberately not enrol in a randomised trial are 
patients with target vessels that supply previously (partly) infarcted 
myocardium because persistent electrocardiographic changes may 
render the diagnosis of a subsequent myocardial infarction difficult 
and sometimes impossible. The same may apply to certain patients 
with previous CABG and end-stage coronary artery disease, who 
likewise often have a higher cardiovascular risk profile and an 
advanced age.
Figure 2. Kaplan-Meier for the primary endpoint and the individual components of the primary endpoint. Kaplan-Meier cumulative incidence 
curves at one year for the primary endpoint target-vessel failure, a composite of cardiac death, target-vessel related myocardial infarction, or 
target-vessel revascularisation (A); cardiac death (B); myocardial infarction (C); and target-vessel revascularisation (D) for both patients of 
the Non-Enrolled TWENTE study and of  the randomised TWENTE trial.
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But what is known about eligible patients who were not enrolled 
in other randomised, comparative DES trials with “real-world” 
patient populations? In fact, such information is sparse. However, 
de Boer et al recently reported for their high-volume PCI centre 
baseline characteristics and one-year all-cause mortality of patients 
who participated in two randomised multicentre trials in all comers 
and compared it to non-participating PCI patients (579 patients 
enrolled vs. 663 non-participants).25 In that study, baseline charac-
teristics differed significantly between trial participants and non-
participants, who were older and had a higher incidence of heart 
failure and unstable clinical syndromes than trial participants).25 In 
addition, all-cause mortality at one-year follow-up was signifi-
cantly higher in non-participants (6.9% vs. 3.1%; p=0.002).
Of note, these all-comers trials included patients with acute 
STEMI,18,19,25 which – on average – have a higher mortality risk. On 
the contrary, the randomised TWENTE trial did not enrol patients 
with acute STEMI,17 who consequently were also not assessed in the 
Non-Enrolled TWENTE study. In addition, de Boer et al addressed 
all non-participating PCI patients, including those who had clear con-
traindications for participation in one of the two randomised trials 
(e.g., patients in shock with very high mortality risk),25 while our own 
study examined only eligible patients who all fulfilled the inclusion 
criteria of the randomised TWENTE trial.17 This may explain differ-
ences in all-cause mortality between non-participants of the study of 
de Boer et al and the Non-Enrolled TWENTE population. A compari-
son of clinical outcome parameters other than mortality was not pos-
sible, as no such data were available for non-enrolled patients of 
other randomised comparative DES trials.
PREVIOUS BYPASS SURGERY AS PREDICTOR OF OUTCOME
In the Non-Enrolled TWENTE population, a history of CABG turned 
out to be the only predictor of TVF. In fact, the rate of TVF became 
identical for both patient populations after removing patients with a 
history of CABG from both patient populations (7.3% vs. 7.3%; 
p=0.99). Implication of this finding may be that particular attention 
should be paid to the distribution of patients with a history of CABG 
between the study arms of comparative DES trials.
Notably, in the randomised TWENTE trial17 the proportion of 
patients with a history of CABG was similar or even higher than in 
some recent trials with second-generation DES in all-comer 
populations.18,20
Study limitations
This trial was performed in a high-volume tertiary centre for PCI by 
five experienced operators with relatively uniform procedural strat-
egies and liberal use of stent postdilatation.17 Therefore, generalisa-
tion of the results may be limited in other settings.
Conclusion
Despite some differences in baseline characteristics, non-enrolled 
and randomised patients did not differ in one-year clinical outcome, 
which was favourable for both populations and may be related to 
the second-generation drug-eluting stents used.
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